Clinical-stage Vaccines Codagenix is a clinical-stage biotechnology company with live-attenuated intranasal vaccine programs for influenza, RSV, dengue, and a COVID-19 candidate (CoviLiv), indicating ongoing near- to mid-term commercialization potential and collaboration opportunities with vaccine distributors or public health partners.

Intranasal Platform The SAVE platform enables genome-level attenuation for intranasal vaccines and oncolytics, presenting a unique value proposition for potential API licensing, co-development, or contract research with pharma companies seeking next-gen mucosal vaccines and viral therapies.

Recent Funding Series B Extension funding and a growing investor base signal financial momentum that can support partnership discussions, milestone-driven collaborations, and non-dilutive or strategic financing options for potential co-development deals.

Key Leadership Recent appointments to leadership and board roles (Chairman and EVP of Animal Health) suggest strengthening governance and strategic focus areas, which can be leveraged in discussions about strategic partnerships, advisory roles, or targeted business development initiatives.

Market Readiness Positive clinical data for CoviLiv and a portfolio spanning respiratory and infectious disease vaccines position Codagenix as a potential supplier or partner for government or multinational health programs seeking novel vaccine solutions and rapid deployment capabilities.